Please try another search
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Name | Age | Since | Title |
---|---|---|---|
Debra Barker | 61 | 2019 | Independent Non-Executive Director |
Sveinung Hole | - | 2010 | Independent Non-Executive Director |
Sally L. Bennett | - | 2020 | Independent Non-Executive Director |
Solange Peters | - | 2023 | Member Scientific Advisory Board |
Shu Kam Mok | 62 | 2023 | Member of Scientific Advisory Board |
Enriqueta Felip | - | 2023 | Member of Scientific Advisory Board |
John Heymach | - | 2023 | Member of Scientific Advisory Board |
Anders Lennart Tullgren | 62 | 2022 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review